CAR.CD22 therapy (Nanocell Therapeutics)

N/A

Report date: 2026/04/23 17:58:18

Base Information

Drug NameCAR.CD22 therapy (Nanocell Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapyCell and gene therapy > Cell therapy > In vivo cell therapy
Mechanisms of ActionAnti-CD22
TargetsCD22
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanoCell Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNanoCell Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A